Prentiss Smith & Co. Inc. Buys New Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Prentiss Smith & Co. Inc. purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) during the 4th quarter, Holdings Channel reports. The fund purchased 4,763 shares of the company’s stock, valued at approximately $650,000.

A number of other large investors also recently modified their holdings of the business. Commerce Bank boosted its position in Neurocrine Biosciences by 2.6% during the third quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Neurocrine Biosciences by 2.7% in the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,302 shares of the company’s stock valued at $496,000 after purchasing an additional 113 shares during the period. Brooklyn Investment Group lifted its position in Neurocrine Biosciences by 99.1% during the fourth quarter. Brooklyn Investment Group now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 115 shares during the period. Tealwood Asset Management Inc. grew its stake in Neurocrine Biosciences by 1.0% during the fourth quarter. Tealwood Asset Management Inc. now owns 11,911 shares of the company’s stock worth $1,626,000 after buying an additional 118 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its position in shares of Neurocrine Biosciences by 42.0% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 531 shares of the company’s stock valued at $72,000 after buying an additional 157 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Barclays increased their price target on shares of Neurocrine Biosciences from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Monday, December 23rd. William Blair reaffirmed an “outperform” rating on shares of Neurocrine Biosciences in a research note on Monday, December 16th. Needham & Company LLC restated a “hold” rating on shares of Neurocrine Biosciences in a research note on Friday, December 20th. HC Wainwright restated a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Monday, December 16th. Finally, UBS Group increased their price target on Neurocrine Biosciences from $142.00 to $162.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $165.40.

Insider Activity at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Ingrid Delaet sold 1,091 shares of the firm’s stock in a transaction on Tuesday, December 17th. The shares were sold at an average price of $135.00, for a total value of $147,285.00. Following the completion of the transaction, the insider now directly owns 2,507 shares of the company’s stock, valued at $338,445. This trade represents a 30.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jude Onyia sold 2,331 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the transaction, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. This represents a 13.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,694 shares of company stock worth $9,676,730. Corporate insiders own 4.30% of the company’s stock.

Neurocrine Biosciences Stock Up 1.2 %

NBIX traded up $1.78 during trading on Wednesday, hitting $152.49. 49,811 shares of the company traded hands, compared to its average volume of 920,650. Neurocrine Biosciences, Inc. has a one year low of $110.95 and a one year high of $157.98. The stock’s fifty day moving average is $135.33 and its 200 day moving average is $131.30. The firm has a market cap of $15.44 billion, a P/E ratio of 40.78 and a beta of 0.33.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.